Research Article

LIFU Alleviates Neuropathic Pain by Improving the KCC2 Expression and Inhibiting the CaMKIV–KCC2 Pathway in the L4–L5 Section of the Spinal Cord

Ye-Hui Liao, Bin Wang, Mo-Xian Chen, Yao Liu, and Li-Juan Ao

School of Rehabilitation, Kunming Medical University, Kunming, 650500 Yunnan Province, China

Correspondence should be addressed to Li-Juan Ao; aolijuan@kmmu.edu.cn

Received 24 November 2020; Revised 13 March 2021; Accepted 25 March 2021; Published 13 April 2021

Academic Editor: Xue-Qiang Wang

Copyright © 2021 Ye-Hui Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Effective treatment remains lacking for neuropathic pain (NP), a type of intractable pain. Low-intensity focused ultrasound (LIFU), a noninvasive, cutting-edge neuromodulation technique, can effectively enhance inhibition of the central nervous system (CNS) and reduce neuronal excitability. We investigated the effect of LIFU on NP and on the expression of potassium chloride cotransporter 2 (KCC2) in the spinal cords of rats with peripheral nerve injury (PNI) in the lumbar 4–lumbar 5 (L4–L5) section.

In this study, rats received PNI surgery on their right lower legs followed by LIFU stimulation of the L4–L5 section of the spinal cord for 4 weeks, starting 3 days after surgery. We used the 50% paw withdraw threshold (PWT50) to evaluate mechanical allodynia. Western blotting (WB) and immunofluorescence (IF) were used to calculate the expression of phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2), calcium/calmodulin-dependent protein kinase type IV (CaMKIV), phosphorylated cyclic adenosine monophosphate response element-binding protein (p-CREB), and KCC2 in the L4–L5 portion of the spinal cord after the last behavioral tests. We found that PWT50 decreased (P < 0.05) 3 days post-PNI surgery in the LIFU− and LIFU+ groups and increased (P < 0.05) after 4 weeks of LIFU stimulation. The expression of p-CREB and CaMKIV decreased (P < 0.05) and that of KCC2 increased (P < 0.05) after 4 weeks of LIFU stimulation, but that of p-ERK1/2 (P > 0.05) was unaffected.

Our study showed that LIFU could effectively alleviate NP behavior in rats with PNI by increasing the expression of KCC2 on spinal dorsal corner neurons. A possible explanation is that LIFU could inhibit the activation of the CaMKIV–KCC2 pathway.

1. Introduction

Neuropathic pain (NP) is defined as pain originating from primary lesions and dysfunction of the somatosensory system, either at the peripheral or central level [1]. Many studies have been conducted on this type of pain, and some progress has been made, but many challenges remain in the clinical treatment of NP [2]. The main clinical manifestations include spontaneous pain, persistent (or paroxysmal) pain, induced pain, paresthesia, numbness, and tingling [2, 3]. As a refractory and chronic pain that can manifest in various ways, including as chronic low back pain or sciatica, NP is a severe problem. It affects 6.9%–10% of the population worldwide and seriously diminishes patient’s quality of life [2], increasing the economic burden on the patient’s family and on society [4–6].

The etiology and mechanism of NP are complicated and unclear. Recently, an increasing amount of evidence has shown that downregulation of potassium chloride cotransporter 2 (KCC2) in the spinal cord plays an important role in NP. KCC2 is an ion transporter protein present in mature neurons of the central nervous system (CNS) and can remove Cl− from the cytoplasm to the extracellular space [7]. After peripheral nerve injury (PNI), the expression of KCC2 on the neuronal membrane is downregulated, and the concentration of Cl− ([Cl−]i) in nerve cells is upregulated, thereby reducing the inhibitory effect of the neurotransmitter γ-aminobutyric acid (GABA) [8–10]. GABA, the main inhibitory neurotransmitter in the mature CNS [11], can bind to the GABA receptor (GABA-R) to promote depolarization of the postsynaptic nerve membrane and mediate hyperpolarization and activity of the neuron [12]. Dysfunction of GABA-R...
eventually reduces inhibition of the spinal cord, leading to hyperexcitability of primary afferent neurons and activation by low-threshold mechanical sensory input. Simultaneously, the primary afferent neurons respond only to high-threshold (nociceptive) inputs under normal circumstances, thereby causing mechanical allodynia and NP [13, 14]. NP has been successfully induced in rats by injecting micromicrobionucleic acid (miRNA), which interferes with the transcription of KCC2, or a KCC2 inhibitor [15, 16]. All results suggest that downregulation of KCC2 after PNI plays an essential role in the development of NP [17]. Many studies have found that increasing the expression of KCC2 significantly relieves NP behavior [9, 18–20]. Therefore, learning how to increase the expression of KCC2 following PNI has great potential value for treating NP.

After PNI, nociceptive stimulation leads to downregulation of the KCC2 expression through a series of intracellular cascades in the brain-derived neurotrophic factor- (BDNF-) tropomyosin receptor kinase B (TrkB) pathway [21, 22]. Calcium/calmodulin-dependent protein kinase type IV (CaMKIV), phosphorylated cyclic adenosine monophosphate response element-binding protein (p-CREB), and phosphorylated extracellular signal–regulated kinase 1/2 (p-ERK1/2) play essential roles in activation of the BDNF–TrkB pathway cascades and downregulation of the KCC2 expression [10, 23, 24]. Rivera confirmed in transgenic mice that activation of the TrkB receptor by BDNF further inhibited the expression of KCC2 at the transcriptional level via the intracellular phosphoinositide phospholipase C gamma (PLCγ) → Ca2+ → CaMKIV → p–CREB cascade [23]. Recently, studies also have found that nociception such as PNI or inflammation can activate the ERK–mitogen-activated protein kinase (MAPK) pathway in the spinal dorsal horn, upregulate the intracellular p-ERK1/2 expression via a Ras→p-ERK1/2 cascade reaction, and inhibit the expression of KCC2 at the transcriptional level, ultimately leading to NP [23, 25, 26]. Therefore, the CaMKIV–KCC2 or p-ERK1/2–KCC2 pathway plays a vital role in NP pathogenesis after PNI (Figure 1).

At present, due to its complicated mechanism, there is still no satisfactory treatment for NP [27, 28]. At the clinical level, conventional painkillers such as tricyclic antidepressants, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), antiepileptic drugs, and weak and strong opioids are often used for symptomatic relief, but with poor efficacy and many side effects [28–30]. Therefore, finding a suitable rehabilitation method for NP would have great clinical significance. As a form of noninvasive neuromodulation, low-intensity focused ultrasound (LIFU) has been confirmed safe for modulating brain activity in patients and animals with seizures [31], Alzheimer’s disease and dementia [32], traumatic brain injury (TBI) [33], and depression [34]. LIFU’s neuromodulatory mechanism includes mechanical, thermal, and cavitation effects [35]. The mechanical effect of LIFU plays an important role in neuromodulation, and its mechanism might be that acoustic radiation forces the bimolecular structure of the cell membrane to stretch through mechanical vibration, thereby interfering with the mechanically sensitive ion channels on the cell membrane and producing the corresponding biological effect [36, 37]. Interestingly, King et al. applied LIFU to the CNS in epileptic rats and found that it could inhibit abnormal epileptic discharges by activating GABAergic neurons in the CNS [38].

However, whether spinal cord stimulation with LIFU can enhance the inhibitory effect and alleviate NP is still unclear. In this study, we loosely ligated the right tibial nerve and common peroneal nerve in rats to create a PNI model. After LIFU stimulation of the L4–L5 spinal cord section, we used the 50% paw withdrawal threshold (PWT50) to evaluate the rats’ mechanical stimulation threshold; WB and IF were used to detect the expression changes of p-ERK1/2, CaMKIV, p-CREB, and KCC2 in the lumbar spinal cord.

2. Materials and Methods

2.1. Animals. We acquired a total of 40 healthy male Sprague-Dawley (SD) rats (weight, 220–300 g) from Kunming Laboratory Animal Center (Kunming, China) for use in the experiment. All rats were housed at 25 °C ± 2 °C on a 12 h reverse light/dark cycle in separate cages (5 rats per cage) and had free access to food and water. All animal protocols were approved by the Animal Ethics Committee of Kunming Medical University (No. KMMU2020352).

2.2. Grouping and Experimental Design. After 1 week of adaptation, all rats were randomly divided into four groups (10 per group): normal group, rats that received neither surgery nor treatment; sham group, rats in which nerves were exposed according to the PNI surgical method but not ligated; and LIFU group and LIFU+ group, rats that received PNI surgery and LIFU stimulation in parallel, except that the ultrasound (US) amplifier was always turned off during treatment in the LIFU+ group.

2.3. PNI Model of NP. We developed the PNI model using the selective nerve injury (SNI) method in strict accordance with the literature [39]. Rats were anesthetized by intraperitoneal (i.p.) injection of 1% sodium pentobarbital (40 mg/kg). We shaved the fur at the right knee joint’s proximal end and made a 1 cm incision. The muscle was separated bluntly, layer by layer, followed by exposure of the three branches of the right sciatic nerve: the tibial nerve, the common peroneal nerve, and the sural nerve. The common peroneal and tibial nerves were loosely ligated with 4–0 silk in three places at 1 mm intervals. We carefully performed manipulations during ligation to avoid injuring the sural nerve. The branches of the right sciatic nerve were exposed but not ligated in sham group rats.

2.4. LIFU Stimulation of the L4–L5 Spinal Cord Section. LIFU stimulation was started on the third day after PNI surgery during the time range of 09:00–15:00 (Figure 2(a)). After administering mild mixed anesthesia with isoflurane and sodium pentobarbital, we fixed the rats on a table and applied a depilatory cream to remove the fur on their backs, exposing the L4–L5 spinal segment. The transducer was fixed on this segment, and the skin was covered, and the transducer gaps filled with an ultrasonic coupling agent (Aquasonic; Parker Laboratories, Fairfield, NJ, USA) without bubbles. Parameters were as follows: sine pulse wave frequency, 4 MHz; duty
cycle (DC), 20%; pulse repetition frequency (PRF), 0.8 KHz; irradiation intensity, 0.65 MPa; and treatment duration, 20 min/d for 4 weeks. We calibrated the beam’s irradiation intensity using a hydrophone (HNR 0500; Onda, Sunnyvale, CA, USA).

2.5. Tissue Preparation. After the last LIFU treatment and behavioral test, rats were sacrificed via overdose of 1% sodium pentobarbital (40 mg/kg), and tissues were harvested for WB (n = 5) and IF (n = 5) staining analysis. For WB, we rapidly collected L4–L5 spinal cord section tissues and stored them at −80°C until use. For IF, rats were perfused with 200 ml prechilled 0.9% saline (4°C) and then 150 ml pre-chilled 0.1 M phosphate buffer (pH 7.4) containing 4% paraformaldehyde (4°C). We harvested the L4–L5 spinal cord section, fixed it in 4% paraformaldehyde overnight at 4°C, and separately dehydrated the slices one by one for 24 h using 20 and 30% sucrose 0.9% saline solution. After being embedded with optimal cutting temperature (OCT) compound, the transverse section slice (8–12 μm thick) of the spinal cord was used for IF or hematoxylin and eosin (H&E) staining.

2.6. Assessment of LIFU Safety. We performed H&E staining to assess the safety of LIFU for the spinal cord. Sections were prepared according to the following procedures: fixation for 30 s, washing in water for 5 min, staining with hematoxylin and eosin. Mechanical allodynia (PWT<sub>50</sub>) was significantly decreased in the LIFU<sup>−</sup> and LIFU<sup>+</sup> groups 3 days after PNI surgery compared with the normal and sham groups. After 3 weeks of LIFU treatment, PWT<sub>50</sub> increased compared with the LIFU<sup>−</sup> group. Each symbol represents the mean ± SEM; ***P < 0.001 against the LIFU<sup>−</sup> and LIFU<sup>+</sup> groups, #P < 0.05 against the LIFU<sup>−</sup> group. One-way ANOVA; n = 10 per group.

![Figure 1: Outline of the current view on the roles of the p-ERK–KCC<sub>2</sub> and CaMKIV–KCC<sub>2</sub> signaling pathways after PNI in the induction of NP. Under normal conditions, KCC<sub>2</sub> extrudes intracellular Cl<sup>−</sup> ions from the cell and maintains the inhibitory effect mediated by GABA receptor. PNI activates TrkB and then obstructs the translation of KCC<sub>2</sub> through the p-ERK–KCC<sub>2</sub> and CaMKIV–KCC<sub>2</sub> signaling pathways.](image1)

![Figure 2: (a) Timeline of experimental protocol. Dps: days postsurgery. (b) Therapeutic effects of LIFU stimulation on NP in PNI rats. Mechanical allodynia (PWT<sub>50</sub>) was significantly decreased in the LIFU<sup>−</sup> and LIFU<sup>+</sup> groups 3 days after PNI surgery compared with the normal and sham groups. After 3 weeks of LIFU treatment, PWT<sub>50</sub> increased compared with the LIFU<sup>−</sup> group. Each symbol represents the mean ± SEM; ***P < 0.001 against the LIFU<sup>−</sup> and LIFU<sup>+</sup> groups, #P < 0.05 against the LIFU<sup>−</sup> group. One-way ANOVA; n = 10 per group.](image2)
solution for 5 min, dipping in 1% acid ethanol five times, staining with eosin solution for 2 min, dipping in graded alcohol (from a high to a low concentration) for 5 min per grade, washing in water for 15 min, dehydration with graded (from a low to a high concentration) alcohol, clearing with xylene, and mounting in resin. We used a digital microscope to observe the results of H&E staining.

2.7. Measurement of Mechanical Allodynia. Behavioral tests were performed in a controlled environment by investigators who were blinded to animal treatments. Each rat was separately placed in a metallic mesh cage (20 × 20 × 15 cm³) and allowed to adapt to the environment for 20 min before the test. We used the up-and-down method to test PWT₅₀ as described in the literature [40]. A series of von Frey (VF) filaments (Stoelting, Wood Dale, IL, USA) with ascending degrees of stiffness (1.4, 2.0, 4, 6, 8, 10, 15, and 26 g) were used to irritate the ipsilateral plantar surface of the PNI paw. The first VF filament to be used was the 6 g filament, and appropriate force was used to bend each filament for 5 s. Licking, lifting, or removing the paw was considered a positive reaction. According to the negative or positive response, we applied a filament at a greater or lower degree of force. PWT₅₀ was calculated as follows:

\[ \text{PWT₅₀} = \frac{1}{10,000} \times 10^{(\log_{10}(3.5) + 1.5)} \]  

The PWT₅₀ test was performed presurgery for 1 day, and pre-LIFU stimulation was performed 1 day/week during the LIFU stimulation period.

2.8. Western Blotting (WB) Analysis. The spinal cord tissue (0.1 g) was dissected, homogenized via US, lysed with radioimmunoprecipitation assay (RIPA) buffer (RIPA: phenylmethylsulfonyl fluoride [PMSF] = 1 ml: 10 µl) on ice for 30 min, and centrifuged at 12,000 rpm for 30 min at 4°C; then, we harvested the supernatants. Total protein concentration was quantified via a bicinchoninic acid (BCA) assay kit (Biomed, Beijing, China), and all samples were equalized to 30 µg/10 µl. Samples (total protein, 30 µg) were resolved by 6%, 10%, and 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore-Sigma, Burlington, MA, USA). We blocked the membranes with 5% fat-free milk at room temperature (RT) for 2 h and then incubated them overnight with primary antibodies at 4°C with gentle shaking. These antibodies included monoclonal antibodies (mAbs) against CaMKIV (1: 2000; Abcam, Cambridge, UK), p-CREB (1: 1000; Cell Signaling Technology [CST], Danvers, MA, USA), p-ERK1/2 (1: 2000; CST), and KCC₂ (1: 1000, CST), as well as glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1: 50,000; ABclonal Technology, Woburn, MA, USA) and β-actin (1: 2000; Santa Cruz Biotechnology, Dallas, TX, USA). The membranes were then incubated with a secondary antibody, horseradish peroxidase (HRP)-labeled anti-rabbit/anti-mouse immunoglobulin G (IgG) HRP-linked antibody (1: 2000; CST), for 90 min at RT. Finally, we visualized and quantified protein bands using enhanced chemiluminescence (ECL; Tanon, Shanghai, China) and an ImageJ software (US National Institutes of Health [NIH], Bethesda, MD, USA). Protein was normalized based on β-actin or GAPDH concentrations.

2.9. Immunofluorescence (IF) Staining. For IF, each slice was washed in phosphate-buffered saline (PBS) for 10 min at RT and then incubated with 5% goat serum and 0.03% Triton X-100 in 0.1 M PBS for 2 h. Then, we incubated the slices in primary antibodies against KCC₂ and p-CREB (respectively, 1:100 and 1:800; CST), as well as antibody against NeuN (1:1000, Abcam), at 4°C overnight. The secondary antibodies (anti-rabbit IgG [heavy + light (H + L) chain], F [ab′]² fragment [Alexa Fluor 488 Conjugate]; anti-mouse IgG [H + L chain], F [ab′]² fragment [Alexa Fluor 594 Conjugate]) were used for incubation at RT in the dark for 2 h. After three 10 min washes with PBS, we incubated the sections with 4',6-diamidino-2-phenylindole (DAPI; Solarbio, Beijing, China). Images were captured under a fluorescence microscope (Olympus Corp., Tokyo, Japan). We used ImageJ software (US National Institutes of Health [NIH], Bethesda, MD, USA) to quantify the density of positive regions.

2.10. Statistical Analyses. Data are presented as mean ± standard deviation (SD). We used SPSS version 23.0 (IBM Corp., Armonk, NY, USA) for all statistical analyses. GraphPad Prism software version 8.0 (GraphPad Software, Inc., San Diego, CA, USA) was used to generate graphs. After verifying that all data were normally distributed, we used one-way analysis of variance (ANOVA) to analyze PWT₅₀, WB, and IF data. P < 0.05 was considered statistically significant.

3. Results

3.1. H&E Staining of the L₄–₅ Spinal Cord Section Was Used to Observe the Safety of LIFU Stimulation. We saw no swelling or nuclear fragmentation of neurons, neutrophil infiltration, or bleeding under cross-sectional magnification (Figure 3(a), x40; Figure 3(b), x100) of this spinal cord section.

3.2. LIFU Alleviated Mechanical Allodynia in PNI Model Rats. As shown in Figure 2(a), we used PWT₅₀ to assess the effect of LIFU stimulation on PNI rats at different times. One day before LIFU stimulation, PWT₅₀ had significantly decreased from 25.3 ± 1.2 g (LIFU⁻ group) and 25.4 ± 1.1 g (LIFU⁺ group) to 6.6 ± 4.6 g and 7.7 ± 3.6 g, respectively (P < 0.05), but there was no statistically significant difference between the two groups (P > 0.05). After LIFU stimulation, PWT₅₀ gradually increased, eventually becoming higher in the LIFU⁺ group (12.1 ± 5.0 g) than in the LIFU⁻ group (6.1 ± 2.2 g) after 3 weeks of LIFU stimulation (P < 0.05) and remaining stable to the end of LIFU stimulation. However, it was still lower in the normal and sham operation groups (P < 0.05), which there was no significant difference (P > 0.05; Figure 2(b)).

3.3. LIFU Stimulation Increased the KCC₂ Expression in the L₄–₅ Spinal Cord Section. After 4 weeks of LIFU stimulation, rats were sacrificed, and the L₄–₅ spinal cord section was harvested for WB (Figure 4(a)) and IF (Figure 5(a))
analyses. The results showed that the expression of the KCC2 protein in rats in the LIFU+ group was upregulated compared with those in the LIFU− group (P < 0.05). There was no difference between the normal and sham groups (P > 0.05; Figures 4(b) and 5(b)).

3.4. LIFU Stimulation Reduced the Expression of CaMKIV and p-CREB but Not of p-ERK1/2 in the L4–L5 Spinal Cord Section of PNI Rats. PNI activates the MAPK pathway and leads to high expression of CaMKIV, p-ERK, and p-CREB [41]. In this study, WB (Figures 4(c)–4(h)) showed that the expression of CaMKIV, p-ERK1/2, and p-CREB increased compared with the LIFU− group (P < 0.05; Figures 4(f) and 4(h)). IF also showed that the expression of p-CREB decreased after LIFU stimulation for 4 weeks compared with the LIFU− group (P < 0.05; Figure 5(d)). Interestingly, there was no statistical difference in the p-ERK1/2 expression between the LIFU− and LIFU+ groups, nor any significant difference in CaMKIV, p-ERK1/2, or p-CREB expression between the normal and sham groups (P > 0.05; Figures 4(d), 4(f), and 4(h)).

4. Discussion

Potassium chloride (K⁺−Cl⁻) cotransporter 2 (KCC2) is the only cationic chloride cotransporter expressed in mammalian neurons. It plays a prominent role in maintaining low [Cl⁻]ₚ, which is necessary for the function of GABAₐ and glycine receptors (GlyRs) and for mediating spinal cord inhibition [8, 10]. After intrathecal application of KCC2 inhibitor 2-[[2S]-2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl]oxy, or DIOA), heat-evoked withdrawal latency and innocuous brush stimulation are significantly reduced [16, 42]. Our experimental data indicated that KCC2 was downregulated in the PNI group, and PWT₅₀ was also lower in this group than in the normal and sham operation groups. All results showed that PNI led to downregulation of the KCC2 expression, which weakens GABAₐ/GlyR-mediated inhibition and then leads to NP [43]. All of the above changes are important factors contributing to the development and maintenance of NP. To further investigate the mechanism of NP, we found that enhancing the KCC2 function pharmacologically restored spinal cord inhibition and reduced allodynia [9]. In our study, pain behavior improved (Figure 2(b)), and the KCC2 expression was upregulated (Figure 4(b)) after 4 weeks of LIFU stimulation. Therefore, the expression of KCC2 in the spinal cord played an important role in the pathogenesis of NP, and upregulation of the KCC2 expression could potentially alleviate NP.

After PNI, the downregulation of KCC2 is closely related to activation of the BDNF–TrkB pathway and intracellular cascade reactions mediated by CaMKIV, p-CREB, and p-ERK [21–24]. Intrathecal application of a TrkB blocker significantly improves downregulation of the KCC2 expression on the membranes of spinal dorsal horn neurons induced by inflammatory pain [44]. In Kitayama’s research, short interfering RNA (siRNA) was used to knock down zinc transporter-1 (ZnT-1), which led to inhibition of the BDNF–TrkB pathway, downregulation of p-CREB, upregulation of KCC2, and improvement of the withdrawal threshold [19]. After intrathecal injection of p-ERK blockers, chronic NP induced by oxaliplatin was also significantly alleviated in rats [45]. López-Alvarez and Li applied electroacupuncture to stimulate rats with chronic constriction injury (CCI) and found that it could effectively improve the KCC2 expression, the mechanical withdrawal threshold, and thermal withdrawal latency [18, 20]. Therefore, inhibition of the BDNF–TrkB pathway and cascade reactions mediated by CaMKIV, p-CREB, and p-ERK, as well as upregulation of the KCC2 expression, could effectively alleviate NP. In this study, we stimulated the spinal cord with LIFU and confirmed the efficacy of LIFU in treating NP. To our knowledge, this study was the first to use LIFU to stimulate the spinal cord in order to regulate NP.

Moreover, we found that CaMKIV and p-CREB were downregulated (Figures 4(f), 4(h), and 5(d)), and KCC2 upregulated (Figures 4(a) and 5(b)) after LIFU stimulation. Upregulation of the KCC2 expression can reduce neural [Cl⁻]ₚ, increase the effect of GABA, and enhance the inhibitory effect of interneuron on the spinal cord, so that the pain threshold of sensory neurons in the spinal cord is reduced.
Figure 4: WB analysis of $\text{KCC}_2$ (a, b), p-ERK1/2 (c, d), CaMK IV (e, f), and p-CREB (g, h) expression in the L4–L5 section of the spinal cord in different groups at 4 weeks post-LIFU treatment. Values, normalized to $\beta$-actin, or GAPDH. Each symbol represents the mean ± SEM; $^*P < 0.05$, $^{**}P < 0.01$, $^{***}P < 0.001$. One-way ANOVA; $n = 5$ rats per assay.
and the behavior of pathological pain is relieved [7, 46]. Therefore, we speculate that LIFU might alleviate pathological pain due to PNI by inhibiting CaMKIV and p-CREB expression and upregulating the KCC2 expression in neurons.

Interestingly, LIFU stimulation did not change the expression of p-ERK1/2 in the spinal cords of PNI rats (Figure 4(d)). While the exact underlying mechanism is unknown, there are several possible explanations. First, in NP rat models, the BDNF-TrkB pathway can activate CaMKIV by increasing the concentration of Ca2+ in neurons via the PLCγ–IP3 pathway, whereas p-ERK is activated through the TrkB–Ras pathway [22, 26]. Second, CaMKIV activation depends on the concentration of Ca2+ in neurons. The mechanical forces of LIFU can affect voltage-gated calcium and sodium channels (VGCCs, VGSCs) in the plasma membrane [35, 47], causing transient intracellular Ca2+ concentration changes in various cells [48]. This mechanism can be used in treatments such as mesenchymal stem cell (MSC) homing [36], neuromodulation in the brain [47], or immunotherapy with tumor US [49]. Therefore, we propose that LIFU might affect CaMKIV activation by interfering with the transient concentration of Ca2+ in neurons but without affecting the p-ERK1/2 expression. However, the specific mechanism of action remains unclear, requiring further research.

As a noninvasive neuromodulatory method, LIFU has many advantages such as higher spatial resolution, greater penetration depth, and no tissue damage [50]. As a nonthermal form of US, LIFU has litter thermal effect on local tissues. When peripheral focused US (pFUS; F = 1.15 MHz; peak negative pressure [PNP] = 4 MPa; DC = 5%) that is used to irradiate muscle and kidney tissue in vitro, the temperatures of these tissues increase by 1.1°C and 0.7°C, respectively [36].

**Figure 5:** Expression of KCC2 (a) p-CREB (c) in the spinal cords of rats in different groups (IF, ×400). Scale bar = 20 μm. Intensities of KCC2 (b) and p-CREB (d) IF in the spinal cords of rats in different groups after 4 weeks of LIFU treatment. Each symbol represents the mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA; n = 5 rats per assay.
In this study, we transected the spinal cord at L4–L5 and performed H&E staining to observe the safety of LIFU on the spinal cord. Our results showed no swelling, nuclear fragmentation of neurons, neutrophil infiltration, or bleeding (Figures 3(a) and 3(b)). Therefore, these results indicated that LIFU was a safe method for treating the spinal cord.

Overall, our study demonstrated that (i) LIFU stimulation of the spinal cord could effectively improve neuropathic pain behavior induced by peripheral nerve injury, which has potential value in the clinical treatment of NP; (ii) LIFU stimulation of the spinal cord might affect the expression of CaMKIV, CREB, and KCC2; and (iii) stimulation of the spinal cord with LIFU was safe.

5. Limitations

Our study had some limitations. First, we established only a short treatment period and did not evaluate the long-term efficacy of US therapy. Second, we selected only one time point at which to measure the expression of CaMKIV, p-CREB, p-ERK, and KCC2. Third, we found that LIFU could affect the expression of CaMKIV, p-CREB, and KCC2, but we failed to explore the specific mechanism by which it affected the expression of the above proteins. Thus, further experiments are needed.

6. Conclusions

We found that LIFU could effectively alleviate NP in rats with PNI by increasing the expression of KCC2 in the spinal dorsal corner. Moreover, LIFU upregulated the expression of KCC2, possibly by inhibiting activation of the CaMKIV–KCC2 pathway.

Abbreviations

NP: Neuropathic pain  
LIFU: Low-intensity focused ultrasound  
PNI: Peripheral nerve injury  
KCC2: Potassium chloride cotransporter 2  
CaMKIV: Calcium/calmodulin-dependent protein kinase type IV  
p-CREB: Phosphorylated cyclic adenosine monophosphate response element-binding protein  
p-ERK1/2: Phosphorylated extracellular signal–regulated kinase 1/2  
GABA: γ-Aminobutyric acid  
BDNF: Brain-derived neurotrophic factor  
TrkB: Tropomyosin receptor kinase B  
CNS: Central nervous system  
dps: Days postsurgery  
PWT50: 50% paw withdrawal threshold.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors wish to acknowledge the language support of Professor Li Jin. This study was supported by the National Natural Science Foundation of China (Nos. 81960421, 81660381, and 82060421). We would like to thank LetPub (https://www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

References

[1] M. Haanpää, N. Attal, M. Backonja et al., “NeuPSIG guidelines on neuropathic pain assessment,” Pain, vol. 152, no. 1, pp. 14–27, 2011.
[2] N. B. Finnerup, S. Haroutounian, P. Kamerman et al., “Neuropathic pain: an updated grading system for research and clinical practice,” Pain, vol. 157, no. 8, pp. 1599–1606, 2016.
[3] D. Bouhassira and N. Attal, “Translational neuropathic pain research: a clinical perspective,” Neuroscience, vol. 338, pp. 27–35, 2016.
[4] D. Grinsell and C. P. Keating, “Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies,” BioMed Research International, vol. 2014, Article ID 698256, 13 pages, 2014.
[5] O. van Hecke, S. K. Austin, R. A. Khan, B. H. Smith, and N. Torrance, “Neuropathic pain in the general population: a systematic review of epidemiological studies,” Pain, vol. 155, no. 4, pp. 654–662, 2014.
[6] L. Colloca, T. Ludman, D. Bouhassira et al., “Neuropathic pain,” Nature Reviews Disease Primers, vol. 3, no. 1, article 17002, 2017.
[7] R. Wright, S. E. Newey, A. Ilie et al., “Neuronal chloride regulation via KCC2 is modulated through a GABABReceptor protein complex,” The Journal of Neuroscience, vol. 37, no. 22, pp. 5447–5462, 2017.
[8] L. Tillman and J. Zhang, “Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K +-Cl- Cotransporter KCC2,” BioMed Research International, vol. 2019, Article ID 8941046, 12 pages, 2019.
[9] M. Gagnon, M. J. Bergeron, G. Lavertu et al., “Chloride extrusion enhancers as novel therapeutics for neurological diseases,” Nature Medicine, vol. 19, no. 11, pp. 1524–1528, 2013.
[10] K. Kaila, T. J. Price, J. A. Payne, M. Puskarjov, and J. Voipio, "Cation-chloride cotransporters in neuronal development, plasticity and disease," Nature Reviews Neuroscience, vol. 15, no. 10, pp. 637–654, 2014.
[11] E. Costa, “From GABAARRECEPTOR diversity emerges a unified vision of GABAAergic inhibition,” Annual Review of Pharmacology and Toxicology, vol. 38, no. 1, pp. 321–350, 1998.
[12] R. L. Macdonald and R. W. Olsen, "GABAARReceptor channels," Annual Review of Neuroscience, vol. 17, no. 1, pp. 569–602, 1994.
[13] B. Duan, L. Cheng, and Q. Ma, "Spinal circuits transmitting mechanical pain and itch," Neuroscience Bulletin, vol. 34, no. 1, pp. 186–193, 2018.
Neural Plasticity

[14] A. J. Todd, "Plasticity of inhibition in the spinal cord," Hand- book of Experimental Pharmacology, vol. 227, pp. 171–190, 2015.

[15] J. Zhang, J. Yu, P. Kannampalli et al., “MicroRNA-mediated downregulation of potassium-chloride-cotransporter and vesicular γ-aminobutyric acid transporter expression in spinal cord contributes to neonatal cystitis-induced visceral pain in rats,” Pain, vol. 158, no. 12, pp. 2461–2474, 2017.

[16] T. M. Austin and E. Delpire, "Inhibition of KCC2 in mouse spinal cord neurons leads to hypersensitivity to thermal stimulation," Anesthesia and Analgesia, vol. 113, no. 6, pp. 1509–1515, 2011.

[17] T. Kitayama, “The role of K(+)–Cl(–)-cotransporter-2 in neuropathic pain,” Neurochemical Research, vol. 43, no. 1, pp. 110–115, 2018.

[18] V. M. Lopez-Alvarez, S. Cobianchi, and X. Navarro, “Chronic electrical stimulation reduces hyperalgesia and associated spinal changes induced by peripheral nerve injury,” Neuromodulation, vol. 22, no. 5, pp. 509–518, 2019.

[19] T. Kitayama, K. Morita, N. Motoyama, and T. Dohi, “Down-regulation of zinc transporter-1 in astrocytes induces neuropathic pain via the brain-derived neurotrophic factor - K(+)Cl(-) co-transporter-2 signaling pathway in the mouse spinal cord,” Neurochemistry International, vol. 101, pp. 120–131, 2016.

[20] S. S. Li, W. Z. Tu, C. Q. Jia et al., “KCC2–GABAA pathway correlates with the analgesic effect of electro-acupuncture in CCI rats,” Molecular Medicine Reports, vol. 17, no. 5, pp. 6961–6968, 2018.

[21] M. Tsuda, “Microglia-mediated regulation of neuropathic pain: molecular and cellular mechanisms,” Biological & Pharmaceutical Bulletin, vol. 42, no. 12, pp. 1959–1968, 2019.

[22] S. Lee-Ihotta, Y. Uchiyama, and S. Kametaka, “Role of the BDNF-TrkB pathway in KCC2 regulation and rehabilitation following neuronal injury: a mini review,” Neurochemistry International, vol. 128, pp. 32–38, 2019.

[23] C. Rivera, J. Voipio, J. Thomas-Crusells et al., “Mechanism of activity-dependent downregulation of the neuron-specific K(+)-Cl(-) cotransporter KCC2,” The Journal of Neuroscience, vol. 24, no. 19, pp. 4683–4691, 2004.

[24] J. A. Coull, S. Beggs, D. Boudreau et al., “BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain,” Nature, vol. 438, no. 7070, pp. 1017–1021, 2005.

[25] K. Obata and K. Noguchi, “MAPK activation in nociceptive neurons and pain hypersensitivity,” Life Sciences, vol. 74, no. 21, pp. 2643–2653, 2004.

[26] W. Ma and R. Quirion, "The ERK/MAPK pathway, as a target for the treatment of neuropathic pain," Expert Opinion on Therapeutic Targets, vol. 9, no. 4, pp. 699–713, 2005.

[27] C. J. Woolf, "Overcoming obstacles to developing new analgesics," Nature Medicine, vol. 16, no. 11, pp. 1241–1247, 2010.

[28] D. P. Kuffler, "Mechanisms for reducing neuropathic pain," Molecular Neurobiology, vol. 57, no. 1, pp. 67–87, 2020.

[29] M. D. DiBonaventura, A. Sadosky, K. Concialdi et al., "The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey," Journal of Pain Research, vol. 10, pp. 2525–2538, 2017.

[30] R. Caruso, G. Ostuzzi, G. Turini et al., "Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis," Pain, vol. 160, no. 10, pp. 2186–2198, 2019.

[31] X. Li, H. Yang, J. Yan, X. Wang, Y. Yuan, and X. Li, "Seizure control by low-intensity ultrasound in mice with temporal lobe epilepsy," Epilepsy Research, vol. 154, pp. 1–7, 2019.

[32] K. Eguchi, T. Shindo, K. Ito et al., "Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in mouse models of dementia - crucial roles of endothelial nitric oxide synthase," Brain Stimulation, vol. 11, no. 5, pp. 959–973, 2018.

[33] S. F. Chen, W. S. Su, C. H. Wu, T. H. Lan, and F. Y. Yang, "Transcranial ultrasound stimulation improves long-term functional outcomes and protects against brain damage in traumatic brain injury," Molecular Neurobiology, vol. 55, no. 8, pp. 7079–7089, 2018.

[34] D. Zhang, H. Li, J. Sun et al., "Antidepressant-like effect of low-intensity Transcranial ultrasound stimulation," IEEE Transactions on Biomedical Engineering, vol. 66, no. 2, pp. 411–420, 2019.

[35] W. J. Tyler, S. W. Lani, and G. M. Hwang, "Ultrasound modulation of neural circuit activity," Current Opinion in Neurobiology, vol. 50, pp. 222–231, 2018.

[36] S. R. Burks, R. M. Lorsung, M. E. Nagle, T. W. Tu, and J. A. Frank, "Focused ultrasound activates voltage-gated calcium channels through depolarizing TRPC1 sodium currents in kidney and skeletal muscle," Theranostics, vol. 9, no. 19, pp. 5517–5531, 2019.

[37] J. Kubanek, P. Shukla, A. Das, S. A. Baccus, and M. B. Goodman, "Ultrasound elicits behavioral responses through mechanical effects on neurons and ion channels in a simple nervous system," The Journal of Neuroscience, vol. 38, no. 12, pp. 3081–3091, 2018.

[38] R. L. King, J. R. Brown, W. T. Newsome, and K. B. Pauly, "Effective parameters for ultrasound-induced _in vivo_ neurostimulation," Ultrasound in Medicine & Biology, vol. 39, no. 2, pp. 312–331, 2013.

[39] J. Decosterd and C. J. Woolf, "Spared nerve injury: an animal model of persistent peripheral neuropathic pain," Pain, vol. 87, no. 2, pp. 149–158, 2000.

[40] S. R. Chaplan, F. W. Bach, J. W. Pogrel, J. M. Chung, and T. L. Yaksh, "Quantitative assessment of tactile allodynia in the rat paw," Journal of Neuroscience Methods, vol. 53, no. 1, pp. 55–63, 1994.

[41] X. Xu, S. Fu, X. Shi, and R. Liu, "Microglial BDNF, PI3K, and p-ERK in the spinal cord are suppressed by pulsed radiofrequency on dorsal root ganglion to ease SNL-induced neuropathic pain in rats," Pain Research and Management, vol. 2019, Article ID 5948686, 2019.

[42] J. C. S. Mapplebeck, L. E. Lorenzo, K. Y. Lee et al., "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes," Cell Reports, vol. 28, no. 3, pp. 390–596.e4, 2019.

[43] S. A. Prescott, "Synaptic inhibition and disinhibition in the spinal dorsal horn," Progress in Molecular Biology and Translational Science, vol. 131, pp. 359–383, 2015.

[44] K. Tsuruga, T. Hashimoto, R. Kato et al., "Plantar injection of formalin in rats reduces the expression of a potassium chloride cotransporter KCC2 in the spinal cord and a kinase inhibitor suppresses this reduction," Biomedical Research, vol. 37, no. 4, pp. 243–249, 2016.

[45] T. Maruta, T. Nemoto, K. Hidaka et al., "Uregulation of ERK phosphorylation in rat dorsal root ganglion neurons contributes to oxaliplatin-induced chronic neuropathic pain," PLoS One, vol. 14, no. 11, article e0225586, 2019.
[46] J. A. Coull, D. Boudreau, K. Bachand et al., “Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain,” *Nature*, vol. 424, no. 6951, pp. 938–942, 2003.

[47] W. J. Tyler, Y. Tufail, M. Finsterwald, M. L. Tauchmann, E. J. Olson, and C. Majestic, “Remote excitation of neuronal circuits using low-intensity, low-frequency ultrasound,” *PLoS One*, vol. 3, no. 10, article e3511, 2008.

[48] I. M. Suarez Castellanos, B. Balteanu, T. Singh, and V. Zderic, “Therapeutic modulation of calcium dynamics using ultrasound and other energy-based techniques,” *IEEE Reviews in Biomedical Engineering*, vol. 9, pp. 177–191, 2016.

[49] K. D. Kim, S. Bae, T. Capece et al., “Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment,” *Nature Communications*, vol. 8, no. 1, article 15365, 2017.

[50] E. Landhuis, “Ultrasound for the brain,” *Nature*, vol. 551, no. 7679, pp. 257–259, 2017.